Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
455actual
Sites
124
Countries
Argentina, Belgium, Brazil +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-03-27 | actual | When the study began enrolling |
| Primary completion | 2026-06-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-19 | actual | The whole study's end, after follow-up |
| First posted | 2019-03-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Open-Angle Glaucoma
- Ocular Hypertension
Interventions
- Drug: Bimatoprost SR — also filed as DURYSTA
- Other: Standard of Care
Primary outcomes
what the primary-completion date above is the date OFDuration of effect of Bimatoprost SR
measured Approximately 24 months
Number of patients experiencing a treatment emergent adverse event
measured Approximately 24 months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed